Viemed Healthcare, Inc. (VMD): Cost of Revenue
$114.82M
Year ended 2025-12-31
$128.28M
Trailing 12 months to 2026-06-30
+28.5%
3-year compound annual growth
+17.5%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $114.82M | +26.1% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $91.05M | +29.7% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $70.22M | +29.7% | 2026-03-04, From 2023-01-01 |
| 2022-12-31 | $54.15M | +24.1% | 2025-03-10, From 2022-01-01 |
| 2021-12-31 | $43.65M | -14.7% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $51.20M | +111.1% | 2022-03-07, From 2020-01-01 |
| 2019-12-31 | $24.25M | +45.3% | 2021-03-03, From 2019-01-01 |
| 2018-12-31 | $16.69M | n/a | 2020-03-04, From 2018-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Viemed Healthcare, Inc. (VMD) | 2025-12-31 | $114.82M | +26.1% |
| Sotera Health Co (SHC) | 2025-12-31 | $518.08M | +4.0% |
| Progyny, Inc. (PGNY) | 2025-12-31 | $984.18M | +7.7% |
| Cryo Cell International Inc (CCEL) | 2025-11-30 | $7.38M | -7.2% |
| Charming Medical Ltd (MCTA) | 2026-03-31 | $35.2K | +127.0% |
| Mangoceuticals, Inc. (MGRX) | 2025-12-31 | $54.4K | -41.7% |
| BioRestorative Therapies, Inc. (BRTX) | 2025-12-31 | $23.8K | -15.1% |
Compare VMD, SHC, PGNY, CCEL side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗